Research programme: glycogen phosphorylase inhibitors - sanofi-aventis

Drug Profile

Research programme: glycogen phosphorylase inhibitors - sanofi-aventis

Alternative Names: AVE 2865; AVE 9423; Glycogen phosphorylase inhibitors research programme - sanofi-aventis

Latest Information Update: 18 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Glycogen phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in Europe (unspecified route)
  • 26 May 2006 In the latest pipeline of February 24, 2006, sanofi-aventis showed only AVE 9423 in preclinical development
  • 26 May 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top